These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 19804254)

  • 1. Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.
    Grieve SM; Ansquer JC; Keech AC
    Future Cardiol; 2006 Nov; 2(6):635-46. PubMed ID: 19804254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2004 Dec; 3():10. PubMed ID: 15574199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
    Saha SA; Arora RR
    Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
    Wierzbicki AS
    Curr Opin Lipidol; 2010 Aug; 21(4):352-8. PubMed ID: 20625256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
    Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
    Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.
    Toth PP
    Int J Clin Pract; 2009 Jun; 63(6):903-11. PubMed ID: 19490201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.
    Chan SY; Mancini GB; Ignaszewski A; Frohlich J
    BMC Clin Pharmacol; 2008 Oct; 8():10. PubMed ID: 18957124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.
    Lancet; 2001 Mar; 357(9260):905-10. PubMed ID: 11289345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
    Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
    Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.].
    Mamedov MN
    Kardiologiia; 2006; 46(12):39-47. PubMed ID: 17310961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.